Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Curevac Ag patent solves the following problem:

Our analysis of this patent is as follows:

Curevac Ag’s patent US 9447431 B2 deals with Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein.
The present invention relates to a nucleic acid, comprising or coding for a coding region, encoding at least one peptide or protein containing a therapeutic protein or a fragment, another or derivative thereof, at least a histone stem-loop and a poly (a) or a polyadenylation signal. Additionally the present invention provides the use of nucleic acid to increase the expression of said encoded peptide or protein, especially for use in gene therapy. It also disclosed its use for the preparation of a pharmaceutical composition, eg for use in gene therapy, especially in the treatment of diseases that are in need of a treatment with a therapeutic peptide or protein , preferably described here. The present invention further describes a method for increasing the expression of a protein or peptide containing a therapeutic protein or a particle, or other derivative thereof, for use in nucleic acid comprising or coding for a histone stem-loop and a poly (A) or a polyadenylation signal.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Application of mRNA for use as a therapeutic against tumour diseases

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Curevac Ag patent solves the following problem:

The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumor, in combination with a aqueous solvent and preferably a cytokine, such as GM-CSF, and a process for preparing the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for the therapy and / or Branch Tomato against cancer.

Our analysis of this patent is as follows:

Curevac Ag’s patent US 9439956 B2 deals with Application of mRNA for use as a therapeutic against tumour diseases.
The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumor, in combination with a aqueous solvent and preferably a cytokine, such as GM-CSF, and a process for preparing the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for the therapy and / or Branch Tomato against cancer.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Application of mRNA for use as a therapeutic against tumor diseases

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Curevac Ag patent solves the following problem:

The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumor, in combination with a aqueous solvent and preferably a cytokine, such as GM-CSF, and a process for preparing the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for the therapy and / or Branch Tomato against cancer.

Our analysis of this patent is as follows:

Curevac Ag’s patent US 9433669 B2 deals with Application of mRNA for use as a therapeutic against tumor diseases.
The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumor, in combination with a aqueous solvent and preferably a cytokine, such as GM-CSF, and a process for preparing the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for the therapy and / or Branch Tomato against cancer.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Application of mRNA for use as a therapeutic against tumour diseases

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Curevac Ag patent solves the following problem:

The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumor, in combination with a aqueous solvent and preferably a cytokine, such as GM-CSF, and a process for preparing the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for the therapy and / or Branch Tomato against cancer.

Our analysis of this patent is as follows:

Curevac Ag’s patent US 9433670 B2 deals with Application of mRNA for use as a therapeutic against tumour diseases.
The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumor, in combination with a aqueous solvent and preferably a cytokine, such as GM-CSF, and a process for preparing the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for the therapy and / or Branch Tomato against cancer.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Curevac Ag patent solves the following problem:

Our analysis of this patent is as follows:

Curevac Ag’s patent US 9421255 B2 deals with Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates.
The present invention is directed to a creative composition or vaccine composition comprising a) an adjuvant component comprising or consisting of at least one immunostimulatory nucleic acid is complexed with a complexing agent; b) an antigen, preferably a protein or peptide antigen and / or a nucleic acid encoding said antigen; and c) a carrier molecule for the joint packaging the adjuvant component of the antigen. The present invention also is directed to the first medical use as a creative composition or vaccine composition and the second medical use as a creative composition or vaccine composition or components thereof for the treatment of diseases, such as infectious or cancerous disease or tumor, as described here. The present invention further discloses kits containing such a composition or vaccine composition.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Composition for treating prostate cancer (PCa)

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Curevac Ag patent solves the following problem:

Our analysis of this patent is as follows:

Curevac Ag’s patent US 9402887 B2 deals with Composition for treating prostate cancer (PCa).
The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably with a mRNA, encoding at least two (preferably different) antigens can aroused a (adaptive) immune response in a mammal which antigens selected from the group consisting of PSA (prostate-Specific antigen), PSMA (prostate-Specific membrane antigen), PSCA (prostate Stem Cell antigen), and steap (Six Transmembrane epithelial antigen of the prostate). invention further relates to a vaccine containing an active (immunostimulatory) composition, and the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and / or vaccines for eliciting an (adaptive) immune response for the treatment of prostate cancer (PCA), preferably of neoadjuvant and / or hormone-rebelled prostate cancers, and diseases or diseases related it. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and / or vaccine.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Structure and use of 5 phosphate oligonucleotides

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Rheinische Friedrich-Wilhelms-Universitt patent solves the following problem:

The vertebrate immune system strengthened in different ways to identify invading pathogens based on certain characteristics of their microbial nucleic acid. Detection of microbial nucleic acid warned the immune system to mount the appropriate type of immune response needed for defense against every kind of pathogen detected. Detection of viral nucleic acid leads to the production of type I interferon (IFN) including IFN- and IFN-, key cytokines for anti-viral defense.

Our analysis of this patent is as follows:

Rheinische Friedrich-Wilhelms-Universitt’s patent US 9381208 B2 deals with Structure and use of 5 phosphate oligonucleotides.
Oligonucleotides that brought free, uncapped 5 phosphate group (s) identified in rig-I, to the induction of type I IFN, IL-18 and IL-1 production. Bacterial RNA formulation type I IFN production. 5 phosphate oligonucleotides and bacteria RNA can be used to induce an anti-viral response or an anti-bacterial solution, in particular, type I IFN and / or IL-18 and / or IL-1 production, vitro and in vivo and for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, tumors, allergies, autoimmune diseases, immunodeficiencies and immune. Single-stranded 5 triphosphate RNA can be used to induce an anti-viral response, an anti-bacterial response, or an anti-tumor response, in particular, type I IFN and / or IL -18 and / or IL-1 production, in a target cell-specific manner.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Composition for treating lung cancer, particularly of non-small lung cancers (NSCLC)

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Curevac Ag patent solves the following problem:

Our analysis of this patent is as follows:

Curevac Ag’s patent US 9352028 B2 deals with Composition for treating lung cancer, particularly of non-small lung cancers (NSCLC).
The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably with a mRNA, encoding at least two (preferably different) antigens can aroused a (adaptive) immune response in a mammal. invention further relates to a vaccine containing the active (immunostimulatory) composition, and the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and / or vaccines for eliciting a (adaptive) immune response for the treatment of lung cancer, especially non-small cell lung cancer (NSCLC), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or disorder associated with them. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and / or vaccine.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Curevac Ag patent solves the following problem:

Our analysis of this patent is as follows:

Curevac Ag’s patent US 9314535 B2 deals with Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids.
The present invention is directed to a creative polymeric carrier molecules according to the generic formula (I) and between them, allowing for efficient transfection of nucleic acid into cells in vivo and in vitro, a polymeric carrier cargo complex formed a nucleic acid and creative polymeric carrier molecule, but also on ways to prepare this creative polymeric carrier molecules and creative polymeric carrier cargo complex. The present invention also provides methods of use and use of this creative polymeric carrier molecules and creative polymeric carrier cargo complex as a medication for the treatment of various diseases, and to prepare a a pharmaceutical composition for the treatment of these diseases.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Moderna Therapeutics, Inc. patent solves the following problem:

There are many problems by way of effecting protein expression. For example, introduced DNA can integrate into the host cell genomic DNA with some frequency, resulting in alteration and / or damage to the host cell genomic DNA. Laing, the heterologous deoxyribonucleic acid (DNA) was introduced into a cell can be inherited by daughter cells (whether or not the heterologous DNA integrated into the chromosome) or by seed.

Our analysis of this patent is as follows:

Moderna Therapeutics, Inc.’s patent US 9303079 B2 deals with Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins.
The invention relates to compositions and methods for the preparation, performance and therapeutic use of polynucleotides, first transcripts and mmRNA molecules.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.